Allostemâ„¢ Shows Positive One-Year Results for Type 2 Diabetes
Creative Medical Technology Holdings, Inc. (CELZ) announced positive one-year follow-up data from a pilot study of CELZ-201 (AlloStemâ„¢) in...
Positive INB-100 Phase 1 Leukemia Trial Results Reported by in8bio
IN8bio’s Phase 1 trial of INB-100, a gamma-delta T cell therapy for complex leukemias like AML, has shown promising...
Corbus Pharmaceuticals Announces Clinical Data for CRB-701
Corbus Pharmaceuticals announced that an abstract for its first-in-human dose-escalation clinical study of CRB-701 (SYS6002) for advanced solid tumors...
Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury
Lineage Cell Therapeutics has launched the DOSED clinical study to evaluate the safety and effectiveness of a new spinal...
Voyager Provides Update on SOD1 ALS Gene Therapy Program
Voyager Therapeutics is halting development of its SOD1 ALS gene therapy, VY9323, after three-month primate data revealed an off-target...
Dr. Sándor Nardai Leads Algernon Phase 2a DMT Stroke Study
Algernon Pharmaceuticals’ subsidiary, Algernon NeuroScience, has appointed Dr. Sándor Nardai as the Principal Investigator for its Phase 2a DMT...
Third Harmonic Bio Announces Phase 1 THB335 Clinical Results & Update
Third Harmonic Bio announced positive Phase 1 results for THB335, an oral KIT inhibitor, paving the way for a...
Padcev® Plus Keytruda® Shows Long-Term Efficacy in Urothelial Cancer
Pfizer and Astellas announced updated results from the Phase 3 EV-302 trial, showing sustained overall survival (OS) and progression-free...
Achieve Life Sciences Positive Orca-OL Trial Results
Achieve Life Sciences announced positive safety results from the second review of their ongoing ORCA-OL trial for cytisinicline, a...
Positive Phase 2 Data for Subcutaneous Migaldendranib at Angiogenesis 2025
Ashvattha Therapeutics announced positive Phase 2 trial data for its subcutaneously administered nanomedicine, Migaldendranib (MGB), designed to treat retinal...